SGX PHARMACEUTICALS, INC.

SAN DIEGO, CA How do I update this listing?

SGX Pharmaceuticals is based out of San Diego. SGX Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of cancer therapeutics. It is developing an internal oncology product pipeline and lead compounds through the application of its proprietary drug discovery platform, Fragments of Active Structures (FAST). The company's pre-clinical development programs include BCR-ABL Kinase Inhibitor Program that focuses on compounds, which inhibit wild-type and Gleevec-resistant mutant forms of BCR-ABL tyrosine kinase, the enzyme that is responsible for CML; and MET Tyrosine Kinase Receptor Inhibitor program that inhibits solid tumors. In addition, it develops JAK2, a non-receptor tyrosine kinase protein; and RAS that is in the lead identification stage, which regulates cell growth. The company has collaboration and license agreements with Novartis Institutes for Biomedical Research, Inc.; Cystic Fibrosis Foundation Therapeutics, Inc.; National Institutes of Health; and Eli Lilly & Company.Whalewisdom has at least 36 Form 4 filings The firm has no submitted 13F filings and does not appear to be an investment advisor.

Create Alert

Contact Info

sgx pharmaceuticals, inc.
10505 ROSELLE STREET
SAN DIEGO CA    92121

Business Phone: 858-558-4850
SEC SIC CODE:
2834-PHARMACEUTICAL PREPARATIONS

Active Schedule 13D and 13G events

Sign in to see

Insider Transactions in the past year

Loading...

Elevate your investments